source
- Trade group warns stalled biosimilar development could forfeit billions in savingsA trade association that represents generic drug makers and biosimilar developers released a new report warning that progress on biosimilar products has slowed. The group says the slowdown threaten…
- Novartis investors grow wary as drug setbacks spark scrutiny of M&A strategyInvestors in Novartis are intensifying their examination of the company’s recent dealmaking after a series of setbacks involving drugs that were brought in through mergers and acquisitions. The hei…